CALGARY, Alberta, Dec. 06, 2017 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX)
announced today that it has repaid, in full, its CAD$68.8 million Loan (the “Loan”). Upon repayment of the Loan, the Company has no
outstanding long-term debt.
Mr. Donald McCaffrey, President and CEO commented, "Retiring the Loan in its entirety significantly strengthens
Resverlogix’s financial position and increases our degrees of freedom as we move forward. We would like to thank Eastern Capital
for its support in providing the letter of credit, which secured the Loan at a very favourable rate. This attractive financing
permitted us to significantly advance the development of apabetalone (RVX-208), including the launch of the Phase 3 trial
BETonMACE."
About Resverlogix
Resverlogix is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET
(bromodomain and extra-terminal) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing
genes. Apabetalone is the first and only BET inhibitor selective for the second bromodomain (BD2) within the BET protein called
BRD4. This selective inhibition of apabetalone on BD2 produces a specific set of biological effects with potentially important
benefits for patients with high-risk cardiovascular disease (CVD), diabetes mellitus (DM), chronic kidney disease, end-stage renal
disease treated with hemodialysis, neurodegenerative disease, Fabry disease, peripheral artery disease and other orphan diseases,
while maintaining a well described safety profile. Apabetalone is the only selective BET bromodomain inhibitor in human clinical
trials. Apabetalone is currently being studied in a Phase 3 trial, BETonMACE, in high-risk CVD patients with type 2 DM and low
high-density lipoprotein (HDL), and is expected to be initiated in a Phase 2a kidney dialysis trial designed to evaluate biomarker
changes and safety parameters in up to 30 patients with end-stage renal disease treated with hemodialysis.
Resverlogix common shares trade on the Toronto Stock Exchange (TSX:RVX).
Follow us on Twitter: @Resverlogix_RVX (https://twitter.com/resverlogix_rvx)
For further information please contact:
Investor Relations
Email: ir@resverlogix.com
Phone: 403-254-9252
Or visit our website: www.resverlogix.com